Category: BIOTECHNOLOGY

"The assumption that we each have a single genome turns out to be off by a trillion-fold," said Geoffrey von Maltzahn, Ph.D., Co-Founder and Chief Executive Officer of Quotient Therapeutics and General Partner, Flagship Pioneering. "All cells accumulate random genetic changes in their DNA, resulting in trillions of unique genomes in the body. Some genetic changes make a cell resistant or vulnerable to disease, while others can cause disease. We started Quotient to study the natural genetics library inside every tissue, discover gene variants that are beneficial, neutral, or disease-causing, and to harness that knowledge to develop the medicines of tomorrow."

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application 17/992,162, entitled, "Compounds and Dosage Regimen for Use in the Prevention or Treatment of Chronic Inflammatory and/or Autoimmune Diseases." Specifically, the resulting patent covers dosing regimens associated with lead asset, vidofludimus calcium (IMU-838), and other salt...

Yourgene’s LightBench is an automated electrophoresis instrument, powered by Ranger® Technology. This platform uses a patent-protected, machine-vision algorithm to interpret and control gel electrophoresis in real time. It delivers accurate size selection for human genomic DNA and includes the ability to perform fragment length analysis for additional quality control.

The BeVigilant OraFusion System stands out as an innovative device in the oral cancer domain, serving as a critical tool in oral cancer detection by identifying specific salivary biomarkers and integrating intelligent software to evaluate clinical risk factors.

"By building sustainable, scalable infrastructure that is capable of detecting biological threats beyond SARS-CoV-2, the TGS program is a global leader in the evolution of biosecurity," said Matt McKnight, General Manager for Biosecurity at Ginkgo Bioworks. "Persistent monitoring can give officials an early warning by offering a view into how pathogens spread across the globe."

"For this incredibly high-risk patient population, speed and data-rich insights matter,” said Gordon Sanghera, PhD, CEO of Oxford Nanopore Technologies. “We are excited to team up with Fabric Genomics to develop an end-to-end analysis tool for the clinical reporting of nanopore sequencing data in paediatric care settings that will make it easier for healthcare providers to leverage genetic insights and, in the future, support the health and wellbeing of children and families.”